Singe Dose, First in Human Study of PF- 06946860 in Healthy Adult Subjects
Completed · Phase 1 · Has a placebo group
Conditions studied: Healthy
In brief
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of PF-06946860 in healthy adult subjects following single ascending doses This is the first clinical study of PF-06946860.
Key facts
- Study ID
- NCT03599063
- Run by
- Pfizer
- People needed
- 63
- Starts
- 2018-07-30
- Expected to finish
- 2019-09-18
- Last updated by the study team
- 2019-11-08
Who can join
Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.
Where it is running
- Pfizer New Haven Clinical Research Unit — New Haven, Connecticut, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.